Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Editors’ Picks >>  7 anti-PD-(L)1 antibodies in Phase III clinical trials: lung cancer is still an important indication competed for

7 anti-PD-(L)1 antibodies in Phase III clinical trials: lung cancer is still an important indication competed for

march 06, 2019 By 1℃

Besides the above products mentioned, there are still 7 anti-PD-(L)1 antibodies in Phase III clinical trials, and lung cancer is still one of the important indications the most companies lay out.

7 anti-PD-(L)1 antibodies in Phase III clinical trials: lung cancer is still an important indication competed for

Among the products in Phase III clinical trials:

The blockbuster imported product atezolizumab is expected to be applied for marketing in China in 2019, which has been approved as a first-line therapy for non-squamous NSCLC in the U.S., being an indication expansion of great significance.

Furthermore, several imported products that enter China are noteworthy.

1. Novartis’ anti-PD-1 antibody PDR001 has been started Phase II clinical trial in China;

2. The cemiplimab co-developed by Regeneron/Sanofi has just started IND in China;

3. The IND application for the anti-PD-L1/TGF-β M7824 developed by Merck KGaA has been approved.

Attached table: Development Progress of Main Anti-PD-(L)1 antibodies in China

Pharmaceutical product

Target

Company

Progress in China

Imported / Chinese-produced

Marketed / late-stage clinical trial indication

Nivolumab

PD-1

BMS

Marketed

Imported

NSCLC

Pembrolizumab

PD-1

MSD

Marketed

Imported

Melanoma

Toripalimab

PD-1

Junshi Biosciences

Marketed

Chinese-produced

Melanoma

Sintilimab

PD-1

Innovent

Marketed

Chinese-produced

HL

Camrelizumab

PD-1

Hengrui Medicine

Applied for production

Chinese-produced

HL

Tislelizumab

PD-1

BeiGene

Applied for production

Chinese-produced

HL

Durvalumab

PD-L1

AstraZeneca

Applied for production

Imported

Stage III NSCLC

Avelumab

PD-L1

Pfizer

Phase III clinical trial

Imported

NSCLC

KN035

PD-L1

Alphamab / 3D Medicines

Phase III clinical trial

Chinese-produced

Bile tract cancer

Atezolizumab

PD-L1

Roche

Phase III clinical trial

Imported

NSCLC, triple-negative breast cancer, bladder cancer

CS1001

PD-L1

CStone Pharmaceuticals

Phase III clinical trial

Chinese-produced

NSCLC, gastric cancer

AK105

PD-1

Akesobio

Phase III clinical trial

Chinese-produced

NSCLC

SHR-1316

PD-L1

Hengrui Medicine

Phase III clinical trial

Chinese-produced

Extensive-stage small cell lung cancer

TQB2450

PD-L1

Chia Tai Tianqing; CBT Pharmaceuticals

Phase III clinical trial

Chinese-produced

Head and neck squamous cell carcinoma

Genolimzumab

PD-1

Genor Biopharma

Phase II clinical trial

Chinese-produced

N/A

KL-A167

PD-L1

Kelun Pharmaceutical

Phase II clinical trial

Chinese-produced

N/A

PDR001

PD-1

Novartis

Phase II clinical trial

Imported

N/A

GLS-010

PD-1

WuXi Biologics; Gloria Pharmaceuticals

Phase II clinical trial

Chinese-produced

N/A

AK103

PD-1

Akesobio; Hansi Biological

Phase II clinical trial

Chinese-produced

N/A

BAT1306

PD-1

Bio-Thera Solutions

Phase II clinical trial

Chinese-produced

N/A

KN046

PD-L1; CTLA4

Alphamab

Phase II clinical trial

Chinese-produced

N/A

Read More:

China has Entered the Era of Tumor Immunotherapy: Updates on the R&D Progress of Anti-PD-(L)1 Antibodies

Register as Visitor to CPhI China 2019!

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
网页对话
live chat